Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
O'Keefe Stevens Advisory, Inc Dominick D'Angelo | “We initiated a position in Baxter during the quarter in the high teens. Baxter spun off its kidney care business as Vantive, closing the sale to Carlyle on January 31, 2025, for approximately $3.8 bil” | BULL | Q1 2026 Apr 24, 2026 | View Pitch |
Pzena Investment Management Richard Pzena | “Baxter International is a leading manufacturer and supplier of everyday hospital essentials, from IV bags and infusion pumps to smart beds and injectable drugs. The company is deeply embedded in hospital operations, with a large installed base of equipment and a broad consumables portfolio that together drive long-term customer relationships. Its core product categories are concentrated among a small number of scaled providers, which supports pricing discipline and stable margins. Despite these strengths, Baxter's stock has fallen nearly 80% from its 2021 peak, as four temporary headwinds have weighed on margins: contract pricing lag from fixed-price hospital contracts, reduced IV bag usage following a supply disruption, stranded costs tied to dialysis divestiture, and a temporary halt in shipments of its new Novum IQ infusion pump. Pzena believes these are transitory issues, with margin recovery underway as contract repricing, volume normalization, and cost elimination progress. The firm projects operating margins returning to ~20% and sees the stock as deeply undervalued at 5.8x normalized earnings. BSD Analysis: Baxter is emerging from a chaotic stretch of supply-chain issues and portfolio turmoil, with margin recovery now showing real traction. The company's spin of its kidney-care unit simplifies the story and clarifies earnings power. Core medical products remain stable with strong hospital relationships. Debt is still elevated, but cash flow is improving and deleveraging is underway. The market is anchored on the worst days of the story, not the improving present. Execution is trending the right way. A credible med-tech recovery with valuation tailwinds.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
